Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (3)
P 2 (1)
P 4 (1)

Trial Status

Recruiting3
Unknown2
Not Yet Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07077486Phase 4RecruitingPrimary

Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease

NCT06999109Not ApplicableNot Yet Recruiting

Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress

NCT05635266Recruiting

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05345899Not ApplicableRecruitingPrimary

Evaluation of Plasma Vitamin C Levels in a Population of Chronic Rheumatism in Immuno-Rheumatology

NCT05686746Phase 2UnknownPrimary

Use of Baricitenib to Maintain of Remission

NCT05275348Not ApplicableUnknown

Delivery of Enhance Fitness Trial

Showing all 6 trials

Research Network

Activity Timeline